Our Pricing

Complete Guide: Why Am I Not Losing Weight On Mounjaro

Published on: June 03, 2026

If you're not losing weight on Mounjaro UK treatment as expected, you're not alone — many patients experience plateaus or slower progress at certain stages. As a UK-registered pharmacy with thousands of weight loss consultations completed, we've identified the most common reasons why Mounjaro may not be delivering optimal results and the evidence-based strategies that can help.

Understanding Normal Mounjaro Weight Loss Patterns

Before assuming Mounjaro isn't working, it's essential to understand what constitutes normal progress. In the landmark SURMOUNT-1 trial, patients on tirzepatide 15mg achieved an average 22.5% body weight reduction over 72 weeks — but this wasn't linear [1]. Most participants experienced rapid initial losses (weeks 0-20), followed by slower but sustained reductions, and occasional plateaus lasting 2-4 weeks.

The MHRA-approved prescribing information notes that individual responses vary significantly based on baseline weight, metabolic health, adherence, and lifestyle factors [2]. Expecting identical results to clinical trial averages overlooks this biological variability. If you've lost 10-15% of your body weight in the first 6 months, you're within the expected range — even if progress feels slower than anticipated.

Weight loss plateaus are a normal metabolic adaptation. As body mass decreases, your basal metabolic rate naturally lowers, requiring fewer calories for maintenance. This doesn't mean Mounjaro has stopped working — it means your body is adjusting to a new equilibrium.

Common Reasons Why Mounjaro May Not Be Working

The most frequent cause we see in clinical practice is insufficient dose escalation. Mounjaro requires gradual titration from 2.5mg to therapeutic doses (10mg or 15mg) over 12-20 weeks [3]. Patients who remain on lower maintenance doses often report suboptimal appetite suppression and slower weight loss. Your UK prescriber should assess whether dose progression has been appropriate for your response.

Inconsistent injection technique can significantly impact absorption. Tirzepatide must be administered subcutaneously into the abdomen, thigh, or upper arm — rotating injection sites prevents lipohypertrophy (fatty lumps) that impair drug absorption [3]. Injecting too shallow (intradermal) or too deep (intramuscular) reduces bioavailability. If you're unsure about technique, request a demonstration from your pharmacist.

Medication interactions and timing issues are frequently overlooked. Mounjaro slows gastric emptying, which can affect absorption of other oral medications taken simultaneously. Additionally, certain medications like corticosteroids, antipsychotics, and some antidepressants promote weight gain and may counteract tirzepatide's effects [4]. Always inform your prescriber of all medications you're taking.

Lifestyle Factors That Limit Results

Even with optimal dosing, Mounjaro cannot overcome persistent caloric surplus. The medication reduces appetite and slows digestion, but unconscious eating behaviours — grazing, liquid calories from alcohol or sweetened beverages, high-calorie condiments — can negate the deficit. Research shows patients who combine tirzepatide with structured dietary support achieve 30-40% greater weight loss than those relying on medication alone [1].

Sleep deprivation and chronic stress elevate cortisol, which promotes insulin resistance and central fat deposition. Studies demonstrate that patients sleeping fewer than 6 hours nightly lose approximately half as much weight on GLP-1 therapies compared to those achieving 7-9 hours [5]. Addressing sleep quality and stress management is not optional — it's fundamental to treatment success.

Medical Conditions That Affect Mounjaro Effectiveness

Undiagnosed or poorly controlled hypothyroidism significantly impairs weight loss on any medication. Thyroid hormones regulate basal metabolic rate — when TSH levels are elevated and free T4 is low, your body burns fewer calories at rest. UK guidelines recommend checking thyroid function before initiating weight loss treatment and monitoring every 6-12 months [6].

Polycystic ovary syndrome (PCOS) affects 10-15% of women of reproductive age and creates insulin resistance that makes weight loss particularly challenging. While tirzepatide's dual GIP/GLP-1 action improves insulin sensitivity more than single-pathway medications, patients with PCOS may require longer treatment duration and adjunctive interventions like metformin to achieve comparable results [4].

Medications prescribed for other conditions can directly interfere with weight loss. Beta-blockers, certain antidepressants (particularly mirtazapine and tricyclics), antipsychotics, and insulin therapy all promote weight gain through various mechanisms. If you've recently started or increased doses of these medications, discuss alternatives with your prescriber — switching from propranolol to a weight-neutral beta-blocker, for example, may restore Mounjaro's effectiveness.

How to Optimise Your Mounjaro Treatment Results

First, ensure you've reached an adequate therapeutic dose. Most patients require 10mg or 15mg weekly for maximum effect — clinical trials showed minimal weight loss difference between 2.5mg and placebo [1]. If you're currently on 5mg or 7.5mg and have tolerated the medication well, request a dose review with your UK prescriber. Dose escalation should continue until you achieve satisfactory appetite suppression or reach the maximum licensed dose.

Protein intake is critical during weight loss to preserve lean muscle mass. Aim for 1.2-1.6g protein per kilogram of ideal body weight daily, distributed across meals. Higher protein intake enhances satiety (working synergistically with tirzepatide), maintains metabolic rate, and prevents the muscle loss that typically accompanies rapid weight reduction [5]. Practical sources include Greek yoghurt, eggs, lean meats, fish, legumes, and protein supplements if needed.

Resistance training twice weekly is non-negotiable for maintaining metabolic rate during weight loss. As you lose weight, your body requires fewer calories — but preserving muscle mass through strength training keeps your metabolism elevated. Studies show patients who combine GLP-1 therapy with resistance exercise maintain 95% of lean mass, compared to 75% in those doing cardio alone [5].

When to Consider Alternative Treatments

If you've been on maximum-dose Mounjaro (15mg) for 16 weeks with less than 5% weight loss despite adherence to lifestyle modifications, it may be appropriate to explore alternatives. While tirzepatide produces superior average results compared to other GLP-1 medications, individual variation means some patients respond better to different mechanisms. Your prescriber may suggest switching to Wegovy (semaglutide) from £135.00, adding adjunctive therapy like Orlistat from £135.00, or investigating underlying medical causes for treatment resistance.

Combination therapy is sometimes warranted for patients with significant treatment-resistant obesity. Orlistat works through a completely different mechanism (fat absorption inhibition) and can be safely combined with Mounjaro under prescriber supervision. This approach may be particularly effective if your diet contains moderate-to-high fat content that limits tirzepatide's effectiveness.

Tracking Progress Beyond the Scales for Not Losing Weight on Mounjaro UK

Body weight alone is an incomplete metric. Many patients who report 'not losing weight' have actually lost significant body fat while gaining lean muscle mass — particularly if they've started resistance training. Weekly weigh-ins can be misleading due to fluid fluctuations, hormonal cycles (in women), sodium intake, and bowel content. More reliable indicators include waist circumference (measure at navel level), clothing fit, progress photographs, and body composition analysis if available.

Non-scale victories often appear before numerical weight changes. Improved glycaemic control (lower HbA1c or fasting glucose), reduced blood pressure, better sleep quality, increased energy levels, and reduced joint pain are all valid markers of metabolic improvement. These changes indicate Mounjaro is working at a physiological level, even if the scales haven't moved as expected.

Consider the context of your starting point. Patients with higher baseline BMI typically lose more absolute weight but may experience plateaus at certain thresholds where the body temporarily stabilises. Conversely, those closer to target weight lose more slowly but may find losses easier to maintain long-term. Comparing your progress to others' experiences on social media creates unrealistic expectations — your journey is individual.

Getting Support from Cured Pharmacy for Mounjaro Weight Loss Stopped

At Cured Pharmacy, our UK-registered clinical team (led by Superintendent Pharmacist Tarun Kumar GPhC 2233073) provides ongoing support throughout your weight loss journey, not just at the point of initial prescription. If you're experiencing a plateau or slower-than-expected results, you can request a medication review through your account portal. Our prescribers will assess your current dose, review your progress, check for potential interactions, and adjust your treatment plan accordingly — all included in your initial consultation fee.

We offer genuine UK-licensed Mounjaro from £124.99 with transparent upfront pricing and discreet next-day delivery across the UK. Unlike some services that require separate consultation fees for follow-up reviews, our model includes ongoing clinical support as part of your treatment package. Every prescription requires clinical assessment by a UK prescriber, ensuring your treatment remains safe and appropriate as your needs evolve.

If Mounjaro proves unsuitable after adequate trial, our team can facilitate transition to alternative treatments. Wegovy (semaglutide) from £124.99 offers a different GLP-1 profile that some patients tolerate or respond to better. Saxenda (liraglutide) from £135.00 provides daily dosing flexibility for those who prefer more frequent administration. All treatment switches require fresh clinical assessment to ensure appropriateness and safety.

Next Steps If You're Not Losing Weight

Start by documenting a detailed 7-day food and activity diary, including portion sizes, timing, and emotional context around eating. This often reveals patterns invisible to casual reflection — late-night snacking, underestimated portions, or stress-driven eating. Share this with your prescriber during your review consultation for targeted intervention.

Request blood tests to rule out medical barriers: full thyroid panel (TSH, free T4, free T3), fasting glucose and HbA1c, lipid profile, and vitamin D. Deficiencies in vitamin D, iron, or B vitamins can impair energy levels and indirectly affect weight loss efforts. Your NHS GP can arrange these tests, or private testing is available if preferred. Bring results to your Mounjaro review appointment for comprehensive assessment.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. https://products.mhra.gov.uk/ [accessed 13 August 2026]
3. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
5. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
6. British Thyroid Foundation. (2022). Thyroid Function Tests: Guidance for UK Healthcare Professionals. BTF Clinical Guidelines. https://www.btf-thyroid.org/ [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary and weight loss outcomes depend on multiple factors including adherence, lifestyle modifications, and underlying health conditions.